Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Tree Physiology|April 18, 2001
Photosynthetic capacity in relation to nitrogen in the canopy of a Quercus robur, Fraxinus angustifolia and Tilia cordata flood plain forestM Kazda, J Salzer, I ReiterOecologia|December 13, 2005
Nutritional differences and leaf acclimation of climbing plants and the associated vegetation in different types of an Andean montane rainforestJ Salzer, S Matezki, M KazdaJournal of Theoretical Biology|February 1, 2014
Modelling the growth of plants with a uniform growth logisticsH G Kilian, D Bartkowiak, M Kazda, et al.Cell Biochemistry and Biophysics|June 25, 2010
On the structure-bounded growth processes in plant populationsH G Kilian, M Kazda, F Király, et al.Diabetes Care|March 15, 2023
Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 DiabetesChristof M Kazda, Juliana M Bue-Valleskey, Jenny Chien, et al.Diabetes Care|March 21, 2023
Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control TrialJuliana M Bue-Valleskey, Christof M Kazda, Chenchen Ma, et al.Diabetes, Obesity & Metabolism|February 14, 2017
Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetesChristof M Kazda, Juan Frias, Irene Foga, et al.Hepatology Communications|May 16, 2018
Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonistCristina B Guzman, Suman Duvvuru, Anthony Akkari, et al.Diabetes Care|December 19, 2015
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 StudiesChristof M Kazda, Ying Ding, Ronan P Kelly, et al.Pageof 1